株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Alchemia Limited:製品パイプライン分析

Alchemia Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 192449
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
Alchemia Limited:製品パイプライン分析 Alchemia Ltd - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 32 Pages
概要

当レポートでは、Alchemia Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Alchemia Limitedの基本情報

Alchemia Limitedの概要

  • 主要情報
  • 企業情報

Alchemia Limited:R&Dの概要

  • 主な治療範囲

Alchemia Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Alchemia Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Alchemia Limited:薬剤プロファイル

  • irinotecan hydrochloride
  • doxorubicin
  • fluorouracil
  • Antibiotic Program
  • bevacizumab
  • carboplatin
  • cetuximab
  • fondaparinux sodium
  • gemcitabine
  • methotrexate
  • 固形腫瘍のための接着斑キナーゼ(FAK)を阻害する小分子
  • vinorelbine tartrate
  • 副甲状腺ホルモンを標的とする小分子
  • 胃抑制ポリペプチドを標的とする小分子
  • 糖尿病のためのGLP-1を標的とする小分子
  • 疼痛のためのNav1.7を標的とする小分子
  • 疼痛のためのオピオイド受容体を標的とする小分子
  • COPDのためのVPAC受容体を標的とする小分子
  • VASTベースの薬剤

Alchemia Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Alchemia Limited:最近のパイプライン動向

Alchemia Limited:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • 肥満症向けのVASTベースの薬剤
    • ACL-16907

Alchemia Limited:企業発表

Alchemia Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08183CDB

Summary

Global Markets Direct's, 'Alchemia Ltd - Product Pipeline Review - 2016', provides an overview of the Alchemia Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alchemia Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Alchemia Ltd
  • The report provides overview of Alchemia Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alchemia Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alchemia Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Alchemia Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alchemia Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alchemia Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alchemia Ltd Snapshot
    • Alchemia Ltd Overview
    • Key Facts
  • Alchemia Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Alchemia Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alchemia Ltd - Pipeline Products Glance
    • Alchemia Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alchemia Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alchemia Ltd - Drug Profiles
    • HA-5FU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HA-Doxorubicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Target CD44 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Respiratory, Oncology, Cardiovascular, Metabolic Disorders, Infectious Disease and Neurology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Gram-Positive Bacterial Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alchemia Ltd - Pipeline Analysis
    • Alchemia Ltd - Pipeline Products by Target
    • Alchemia Ltd - Pipeline Products by Route of Administration
    • Alchemia Ltd - Pipeline Products by Molecule Type
    • Alchemia Ltd - Pipeline Products by Mechanism of Action
  • Alchemia Ltd - Dormant Projects
  • Alchemia Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ACL-16907
      • VAST Based Drug For Obesity
  • Alchemia Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alchemia Ltd, Key Facts
  • Alchemia Ltd - Pipeline by Indication, 2016
  • Alchemia Ltd - Pipeline by Stage of Development, 2016
  • Alchemia Ltd - Monotherapy Products in Pipeline, 2016
  • Alchemia Ltd - Phase II, 2016
  • Alchemia Ltd - Preclinical, 2016
  • Alchemia Ltd - Discovery, 2016
  • Alchemia Ltd - Pipeline by Target, 2016
  • Alchemia Ltd - Pipeline by Route of Administration, 2016
  • Alchemia Ltd - Pipeline by Molecule Type, 2016
  • Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016
  • Alchemia Ltd - Dormant Developmental Projects,2016
  • Alchemia Ltd - Discontinued Pipeline Products, 2016
  • Alchemia Ltd, Subsidiaries

List of Figures

  • Alchemia Ltd - Pipeline by Top 10 Indication, 2016
  • Alchemia Ltd - Pipeline by Stage of Development, 2016
  • Alchemia Ltd - Monotherapy Products in Pipeline, 2016
  • Alchemia Ltd - Pipeline by Target, 2016
  • Alchemia Ltd - Pipeline by Molecule Type, 2016
  • Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016
Back to Top